Drug Companies Should Be Incentivized To Develop New Antibiotics

Financial Times: Pull together to prevent a superbug apocalypse
Editorial Board

“…Although [the final report of the Review on Antimicrobial Resistance] is full of excellent proposals, early comments have targeted one of its most eye-catching and least well-thought-out ideas: a ‘play or pay’ scheme. Pharmaceutical companies would either pay a levy into a pooled global fund to support antibiotic research and development or demonstrate that they are investing an equivalent amount or more in R&D. While the global pharma industry bears some responsibility for the current crisis — most companies cut back hard on antibiotic development because they foresaw a poor potential return on these new drugs — the best way to refill the pipeline is through offering better incentives at all stages, from early research through clinical trials to regulatory approval. … ‘Play or pay’ is potentially divisive and threatens to alienate the industry whose wholehearted cooperation will be essential if the world is indeed to defeat superbugs. … Action along the lines recommended by Lord [Jim] O’Neill is urgent and should not be deflected by arguments over a ‘play or pay’ levy. Antibiotic resistance must be high on the agenda at key global meetings this year…” (5/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.